Molecular design to enhance the penetration into the retina via ocular instillation

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 19, 2008, Pages 5174-5177

  Shirasaki, Yoshihisa ^a   Takahashi, Hiroaki ^a   Yamaguchi, Masazumi ^a   Inoue, Jun ^a  

^a SENJU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Aqueous humor; Aqueous solubility; Calpain inhibitors; Ethylene glycol chain; Oral absorption; Retina; Retinal penetration

Indexed keywords

CALPASTATIN; CARBOXYMETHYLCELLULOSE; ETHYLENE GLYCOL DERIVATIVE; METHOXYETHYLENE GLYCOL; SNJ 1919; SNJ 1945; SNJ 1953; SNJ 1955; SNJ 1957; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTERIOR EYE CHAMBER; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG EXPOSURE; DRUG PENETRATION; DRUG SOLUBILITY; HYDROPHILICITY; LIPOPHILICITY; MONKEY; NONHUMAN; RABBIT; RETINA;

ADMINISTRATION, ORAL; ANIMALS; CALPAIN; CARBAMATES; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; INJECTIONS, INTRAVENOUS; MACACA FASCICULARIS; MOLECULAR STRUCTURE; RABBITS; RETINA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 52049083217     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.08.089     Document Type: Article

References (17)

1. Congdon N., O'Colmain B., Klaver C.C., Klein R., Muñoz B., Friedman D.S., Kempen J., Taylor H.R., Mitchell P., and Eye Diseases Prevalence Research Group. Arch. Ophthalmol. 122 (2004) 477
2. Ghate D., and Edelhauser H.F. Expert Opin. Drug Deliv. 3 (2006) 275
3. Hughes P.M., Olejnik O., Chang-Lin J.E., and Wilson C.G. Adv. Drug Deliv. Rev. 57 (2005) 2010
4. Steven B.K. Curr. Drug Metab. 4 (2003) 213
5. Acheampong A.A., Shackleton M., John B., Burke J., Wheeler L., and Tang-Liu D. Drug Metab. Dispos. 30 (2002) 421
6. Harris A., Arend O., Arend S., and Martin B. Acta Ophthalmol. Scand. 74 (1996) 569
7. Inoue J., Oka M., Aoyama Y., Kobayashi S., Ueno S., Hada N., Takeda T., and Takehana M. J. Ocul. Pharmacol. Ther. 20 (2004) 1
8. Tamaki Y., Nagahara M., Araie M., Tomita K., Sandoh S., and Tomidokoro A. J. Ocul. Pharmacol. Ther. 17 (2001) 403
9. Erkin E.F., Tarhan S., Kayikçioǧlu O.R., Deveci H., Güler C., and Göktan C. Eur. J. Ophthalmol. 14 (2004) 211
10. Grunwald J.E. Invest. Ophthalmol. Vis. Sci. 31 (1990) 521
11. Shirasaki Y. J. Pharm. Sci. 97 (2008) 2462
12. Mannermaa E., Vellonen K., and Urtti A. Adv. Drug Deliv. Rev. 58 (2006) 1136
13. Shirasaki Y., Miyashita H., Yamaguchi M., Inoue J., and Nakamura M. Bioorg. Med. Chem. 13 (2005) 4473
14. Shirasaki Y., Yamaguchi M., and Miyashita H. J. Ocul. Pharmacol. Ther. 6 (2006) 417
15. Oka T., Walkup R.D., Tamada Y., Nakajima E., Tochigi A., Shearer T.R., and Azuma M. Neuroscience 141 (2006) 2139
16. Harbeson S.L., Abelleira S.M., Akiyama A., Barrett R., Carroll R.M., Straub J.A., Tkacz J.N., Wu C., and Musso G.F. J. Med. Chem. 37 (1994) 2918
17. Cuerrier D., Moldoveanu T., Inoue J., Davies P.L., and Campbell R.L. Biochemistry 45 (2006) 7446